Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Associate Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.

Development of new drugs for personalized cancer chemotherapy

In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
E-167
Québec, Québec
Canada G1L 3L5

Latest news

Data not available

33 entries « 2 of 4 »

Morin N, Bruneau J, Fortin S, Brasseur K, Leblanc V, Asselin E, Berube G

New testosterone derivatives as semi-synthetic anticancer agents against prostate cancer: synthesis and preliminary biological evaluation.

Journal Article

Med Chem, 11 (6), pp. 531-9, 2015, ISSN: 1573-4064.

Abstract | Links:

Fortin S, Wei Lianhu, Kotra LP, C-Gaudreault R

Novel Cytocidal Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl) Benzenesulfonates and Benzenesulfonamides with Affinity to the Colchicine-Binding Site: Is the Phenyl 2-Imidazolidinone Moiety a New Haptophore for the Design of New Antimitotics?

Journal Article

Open J Med Chem, 5 , pp. 9-22, 2014, ISSN: 2164-313X.

| Links:

Fortin S, Brasseur K, Morin N, Asselin E, Berube G

New platinum(II) complexes conjugated at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: design, synthesis, structure-activity relationships and biological evaluation.

Journal Article

Eur J Med Chem, 68 , pp. 433-43, 2013, ISSN: 0223-5234.

Abstract | Links:

Fortin S, Berube G

Advances in the development of hybrid anticancer drugs.

Journal Article

Expert Opin Drug Discov, 8 (8), pp. 1029-47, 2013, ISSN: 1746-0441.

Abstract | Links:

Charest-Morin X, Fortin S, Lodge R, Roy C, Gera L, C-Gaudreault R, Marceau F

Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling.

Journal Article

Pharmacol Res, 71 , pp. 44-52, 2013, ISSN: 1043-6618.

Abstract | Links:

Marceau F, Bouthillier J, Houle Steeve, Sabourin T, Fortin JP, Morissette G, Lodge R, Fortin S, C-Gaudreault R, Bawolak MT, Koumbadinga MT, Gérémy A, Roy C, Charest-Morin X, Gera L

Bradykinin receptors: agonists, antagonists, expression, signaling and adaptation to sustained stimulation

Journal Article

J Angioedema, 1 (December), pp. 9-17, 2013, ISSN: 2365-5686.

| Links:

Saha P, Fortin S, Leblanc V, Parent S, Asselin E, Berube G

Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.

Journal Article

Steroids, 77 (11), pp. 1113-22, 2012, ISSN: 0039-128X.

Abstract | Links:

Turcotte V, Fortin S, Vevey F, Coulombe Y, Lacroix J, Cote MF, Masson JY, C-Gaudreault R

Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks.

Journal Article

J Med Chem, 55 (13), pp. 6194-208, 2012, ISSN: 0022-2623.

Abstract | Links:

Saha P, Descoteaux C, Brasseur K, Fortin S, Leblanc V, Parent S, Asselin E, Berube G

Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.

Journal Article

Eur J Med Chem, 48 , pp. 385-90, 2012, ISSN: 0223-5234.

Abstract | Links:

Fortin S, Wei L, Moreau E, Lacroix J, Cote MF, Petitclerc E, Kotra LP, Gaudreault RC

Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships.

Journal Article

Eur J Med Chem, 46 (11), pp. 5327-42, 2011, ISSN: 0223-5234.

Abstract | Links:

33 entries « 2 of 4 »
Signaler des ajouts ou des modifications

Active projects

  • Appui financier du Fonds de recherche de l’Hôpital Saint-François d'Assise pour le support de doctorants.es au laboratoire du Dr Sébastien Fortin, Subvention, Fondation de l'Université Laval, from 2020-05-01 to 2022-04-30
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
  • Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
  • Conception de nouveaux agents anticancéreux ciblant les mécanismes de réparation et de réplication de l'ADN en vue de leur utilisation en médecine personnalisée, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2018-07-01 to 2022-06-30
  • Conception de nouveaux agents anticancéreux ciblant les mécanismes, Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2018-07-01 to 2022-06-30
  • Les phénylureidobenzènesulfonates, une nouvelle thérapie de différenciation pour le traitement de la leucémie myéloïde aiguë : preuve de concept, Subvention, Fondation de l'Université Laval, from 2020-02-01 to 2022-01-31

Recently finished projects

  • Soutien à la recherche du Fonds de recherche de l'Hôpital Saint-François d'Assise, Subvention, Fondation de l'Université Laval, from 2016-05-01 to 2020-04-30
Data provided by the Université Laval research projects registery